# Dietary ellagic acid inhibiting gastrointestinal pathogens by modulation of microbiome-metabolite-immune axis

**Authors:** Li-Na Mei, Jia-Shan Shen, Yu Duan, Zhuo-Qi Shi, Hui-Zhen Peng, Xiao-Dong Luo

PMC · DOI: 10.1007/s13659-025-00584-x · Natural Products and Bioprospecting · 2026-02-01

## TL;DR

Ellagic acid, found in fruits and nuts, helps restore gut health by boosting good bacteria and reducing harmful pathogens.

## Contribution

The study reveals ellagic acid's novel role in modulating gut microbiota and immune responses to combat antibiotic-induced infections.

## Key findings

- Ellagic acid promotes gut microbiota recovery and increases microbial diversity.
- It activates Gpr41 and Gpr43 via SCFAs to inhibit the NF-ĸB pathway.
- The compound reduces pathogen overgrowth and offers an alternative to antibiotics.

## Abstract

Antibiotic-induced depletion of the gut microbiota facilitated the colonization of vancomycin-resistant Enterococci (VRE) in the gastrointestinal tract, and then increased patients' susceptibility to secondary infections. Ellagic acid, a major constituent of fruits and nuts, showed various bioactivities except for antibacterial. Interestingly, it promoted the recovery of gut microbiota, enhanced microbial diversity and stimulated the proliferation of probiotic gut microbes, and then ameliorated the overgrowth of pathogens in vivo in our experiment. Moreover, ellagic acid activated Gpr41 and Gpr43 mainly by promoting the production of short chain fatty acids (SCFAs) such as acetic acid and propionic acid to inhibit the NF-ĸB signaling pathway. Then the dietary supplement with ellagic acid might treat infected gut to avoid antibiotic-associated intestinal diseases, and the finding also provided a novel strategy for exploring antibacterial agent besides screening in vitro.

The online version contains supplementary material available at 10.1007/s13659-025-00584-x.

## Linked entities

- **Genes:** FFAR3 (free fatty acid receptor 3) [NCBI Gene 2865], FFAR2 (free fatty acid receptor 2) [NCBI Gene 2867]
- **Chemicals:** ellagic acid (PubChem CID 5281855), acetic acid (PubChem CID 176), propionic acid (PubChem CID 1032)

## Full-text entities

- **Genes:** Ffar3 (free fatty acid receptor 3) [NCBI Gene 233080] {aka Gm478, Gpr41}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Ffar2 (free fatty acid receptor 2) [NCBI Gene 233079] {aka GPCR43, Gpr43}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FFAR2 (free fatty acid receptor 2) [NCBI Gene 2867] {aka FFA2R, GPR43}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, FFAR3 (free fatty acid receptor 3) [NCBI Gene 2865] {aka FFA3R, GPR41}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}
- **Diseases:** opportunistic infection (MESH:D009894), non-alcoholic fatty liver disease (MESH:D065626), diarrheal illness (MESH:D004403), intestinal diseases (MESH:D007410), liver damage (MESH:D056486), proinflammatory factors (MESH:D005171), weight loss (MESH:D015431), bacteremia (MESH:D016470), dysbiosis (MESH:D064806), diarrhea (MESH:D003967), pneumonia (MESH:D011014), weight gain (MESH:D015430), inflammation (MESH:D007249), VRE infection (MESH:D007239), bacterial infection (MESH:D001424), VRE (MESH:D060467), urinary tract infections (MESH:D014552), sepsis (MESH:D018805)
- **Chemicals:** azithromycin (MESH:D017963), Acetate (MESH:D000085), valeric acid (MESH:C038780), acetic acid (MESH:D019342), Isopropyl ether (MESH:C011779), nitrofurantoin (MESH:D009582), daptomycin (MESH:D017576), SDS (MESH:D012967), Ellagic acid (MESH:D004610), amoxicillin (MESH:D000658), kanamycin (MESH:D007612), AMP (MESH:D000667), valerate (MESH:D014631), propionate (MESH:D011422), propionic acid (MESH:C029658), phosphoric acid (MESH:C030242), linezolid (MESH:D000069349), fosfomycin (MESH:D005578), CTAB (MESH:D000077286), TSA (-), VAN (MESH:D014640), SCFA (MESH:D005232)
- **Species:** Bacteroides acidifaciens (species) [taxon 85831], Escherichia coli (E. coli, species) [taxon 562], Punica granatum (granado, species) [taxon 22663], Mus musculus (house mouse, species) [taxon 10090], Pseudomonadota (proteobacteria, phylum) [taxon 1224], Homo sapiens (human, species) [taxon 9606], Bacteroides (genus) [taxon 816], Ligilactobacillus murinus (species) [taxon 1622], Proteus mirabilis (species) [taxon 584], Klebsiella pneumoniae (species) [taxon 573], Bacillota (clostridial firmicutes, phylum) [taxon 1239], gut metagenome (species) [taxon 749906], Akkermansia muciniphila (species) [taxon 239935], Lactobacillus johnsonii (species) [taxon 33959], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Escherichia albertii (species) [taxon 208962], [Clostridium] innocuum (species) [taxon 1522], Actinomycetota (actinobacteria, phylum) [taxon 201174], Limosilactobacillus reuteri (species) [taxon 1598], Staphylococcus aureus (species) [taxon 1280], Enterococcus faecalis (species) [taxon 1351], Bacteroidota (Bacteroides-Cytophaga-Flexibacter group, phylum) [taxon 976]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12860781/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12860781/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12860781/full.md

---
Source: https://tomesphere.com/paper/PMC12860781